Wnt signaling in cancer

Cold Spring Harbor Perspectives in Biology

Volumn 4, Issue 5, 2012, Pages 9-

  Polakis, Paul ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TUMOR SUPPRESSOR PROTEIN;

BIOLOGICAL MODEL; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; WNT SIGNALING PATHWAY;

EPIGENESIS, GENETIC; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS; WNT SIGNALING PATHWAY;

EID: 84865109330     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a008052     Document Type: Article

References (87)

1. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, et al. 2009. Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci 106: 3925-3929.
2. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA. 2009. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-2172.
3. Angus-Hill ML, Elbert KM, Hidalgo J, Capecchi MR. 2011. T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Proc Natl Acad Sci 108: 4914-4919.
4. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. 2003. Regulation of cyclooxygenase- 2 expression by the Wnt and ras pathways. Cancer Res 63: 728-734.
5. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, et al. 2009. β-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15: 2731-2738.
6. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. 2004. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6: 497-506.
7. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, et al. 2011. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet 43: 964-968.
8. Bjorklund P, Svedlund J, Olsson AK, Akerstrom G, Westin G. 2009. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS ONE 4: e4243.
9. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. 2005. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 310: 1504-1510.
10. Chan AT, Ogino S, Fuchs CS. 2007. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142.
11. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, et al. 2011a. EZH2- mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res 71: 4028-4039.
12. Cheng CK, Li L, Cheng SH, Ng K, Chan NP, Ip RK, Wong RS, Shing MM, Li CK, Ng MH. 2011b. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia. Blood 118: 6638-6648.
13. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
14. Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL. 2004. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 100: 2084-2092.
15. Clements WM, Lowy AM, Groden J. 2003. Adenomatous polyposis coli/β-catenin interaction and downstream targets: Altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer 3: 113-120.
16. Cong F, Zhang J, Pao W, Zhou P, Varmus H. 2003. A protein knockdown strategy to study the function of β-catenin in tumorigenesis. BMC Mol Biol 4: 10.
17. Cuilliere-Dartigues P, El-Bchiri J, Krimi A, Buhard O, Fontanges P, Flejou JF, Hamelin R, Duval A. 2006. TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4- mediated transcription. Oncogene 25: 4441-4448.
18. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. 2007. The soluble Wnt receptor Frizzled8CRD- hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 67: 5371-5379.
19. Ekstrom EJ, Sherwood V, Andersson T. 2011. Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion. PLoS ONE 6: e18674.
20. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. 2005. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435: 964-968.
21. Fre S, Pallavi SK, Huyghe M, Lae M, Janssen KP, Robine S, Artavanis-Tsakonas S, Louvard D. 2009. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci 106: 6309-6314.
22. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS. 2011. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
23. Gottardi CJ, Wong E, Gumbiner BM. 2001. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 153: 1049-1060.
24. Green DW, Roh H, Pippin JA, Drebin JA. 2001. β-catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 101: 16-20.
25. Howe LR, Brown AM. 2004. Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41.
26. Hu T, Li C. 2011. Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer 9: 236.
27. Huff V. 2011. Wilms' tumours: About tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11: 111-121.
28. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
29. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al. 2008. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13: 529-541.
30. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. 2010. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
31. Kim JS, Crooks H, Foxworth A, Waldman T. 2002. Proof-ofprinciple: oncogenic β-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1: 1355-1359.
32. Klaus A, Birchmeier W. 2008. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
33. Kongkham PN, Northcott PA, Croul SE, Smith CA, Taylor MD, Rutka JT. 2010. The SFRP family of WNTinhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 29: 3017-3024.
34. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, Srivastava D. 2011. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat Cell Biol 13: 1244-1251.
35. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205.
36. Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P. 2004. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74: 1043-1050.
37. Lilien J, Balsamo J. 2005. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr Opin Cell Biol 17: 459-465.
38. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. 2000. β-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci 97: 4262-4266.
39. Mahmoudi T, Boj SF, Hatzis P, Li VS, Taouatas N, Vries RG, Teunissen H, Begthel H, Korving J, Mohammed S, et al. 2011. The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis. PLoS Biol 8: e1000539.
40. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al. 2007.Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 316: 1043-1046.
41. Malanchi I, Huelsken J. 2009. Cancer stem cells: Never Wnt away from the niche. Curr Opin Oncol 21: 41-46.
42. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, et al. 2008. Cutaneous cancer stem cell maintenance is dependent onβ-catenin signalling. Nature 452: 650-653.
43. Marvin ML, Mazzoni SM, Herron CM, Edwards S, Gruber SB, Petty EM. 2011. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A 155A: 898-902.
44. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. 2009. WNTsignaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-Mβ-231 xenograft growth. Breast Cancer Res 11: R32.
45. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. 2006. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66: 3541-3549.
46. Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, et al. 2011. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell 20: 583-596.
47. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB. 2010. Colorectal tumors are effectively eradicated by combined inhibition of fbg-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 70: 7253-7263.
48. Morin PJ, Vogelstein B, Kinzler KW. 1996. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci 93: 7950-7954.
49. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. 2011. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large β-cell lymphomas of germinal- center origin. Nat Genet 42: 181-185.
50. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, et al. 2011. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471: 235-239.
51. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, et al. 2006. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci 103: 12098-12102.
52. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. 2009. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62.
53. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. 2011. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20: 119-131.
54. Oshima M, Taketo MM. 2002. COX selectivity and animal models for colon cancer. Curr Pharm Des 8: 1021-1034.
55. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, et al. 2011. Inactivating mutations of acetyltransferase genes in β-cell lymphoma. Nature 471: 189-195.
56. Phesse TJ, Parry L, Reed KR, Ewan KB, Dale TC, Sansom OJ, Clarke AR. 2008. Deficiency of Mbd2 attenuates Wnt signaling. Mol Cell Biol 28: 6094-6103.
57. Polakis P. 2007. The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51.
58. Reya T, Clevers H. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850.
59. Rodriguez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
60. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. 2001. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 61: 6563-6568.
61. Ruteshouser EC, Robinson SM, Huff V. 2008.Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47: 461-470.
62. Salahshor S, Woodgett JR. 2005. The links between axin and carcinogenesis. J Clin Pathol 58: 225-236.
63. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. 2003. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34: 145-147.
64. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al. 2000. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250.
65. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
66. Smartt HJ, Greenhough A, Ordonez-Moran P, Talero E, Cherry CA, Wallam CA, Parry L, Al Kharusi M, Roberts HR, Mariadason JM, et al. 2011. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut doi: 10.1136/gutjnl-2011- 300817.
67. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100: 8418-8423.
68. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
69. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, et al. 2008. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98: 1147-1156.
70. Takagi H, Sasaki S, Suzuki H, Toyota M, Maruyama R, Nojima M, Yamamoto H, Omata M, Tokino T, Imai K, et al. 2008. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol 43: 378-389.
71. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L. 2008. A genome-wide RNAi screen for Wnt/bcatenin pathway components identifies unexpected roles for TCF transcription factors in cancer. ProcNatl Acad Sci 105: 9697-9702.
72. Teo JL, Kahn M. 2011. The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev 62: 1149-1155.
73. Tetsu O, McCormick F. 1999. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
74. van deWetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al. 2002. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250.
75. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, et al. 2005. Notch/g-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963.
76. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, et al. 2009. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521-523.
77. van Veelen W, Le NH, Helvensteijn W, Blonden L, Theeuwes M, Bakker ER, Franken PF, van Gurp L, Meijlink F, van der Valk MA, et al. 2011. β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 60: 1204-1212.
78. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. 2003. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9: 1291-1300.
79. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. 2011. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 17: 4341-4354.
80. Wang D, Mann JR, DuBois RN. 2004. WNTand cyclooxygenase- 2 cross-talk accelerates adenoma growth. Cell Cycle 3: 1512-1515.
81. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. 2010. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science 327: 1650-1653.
82. Willert K, Jones KA. 2006. Wnt signaling: Is the party in the nucleus? Genes Dev 20: 1394-1404.
83. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, et al. 2011a. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 43: 4437-4446.
84. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. 2011b. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480: 118-122.
85. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, et al. 2004. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23: 6170-6174.
86. Zeng G, Apte U, Cieply B, Singh S, Monga SP. 2007. siRNAmediated β-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9: 951-959.
87. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. 2007. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.